Results 121 to 130 of about 5,542 (243)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

ClinicoEconomics and Outcomes Research, 2018
Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S   +6 more
doaj  

Limited Options to Manage Specialty Drug Spending [PDF]

, 2012
Outlines rising trends in costs of and spending on specialty drugs; health plans' efforts to curb specialty drug spending, including patient cost sharing and utilization management; and efforts to integrate medical and pharmaceutical ...
Divya R. Samuel, Ha T. Tu
core  

Medicine Development and Access for Rare Diseases: Can We Do Better?

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Recent advances in molecular biology and genomics have significantly enhanced our understanding of rare diseases. While enabling the development of highly targeted therapies, it also leads to complexity in the development, regulation, and accessibility of orphan medicines.
Carla E. M. Hollak, Noa Rosenberg, Colinda Post, Nina Stolwijk, Evert Manders, Daphne Schoenmakers, Bart Penninx, Niels Reijnhout, Kathelijn Verdeyen, Roel Jonker, Annet M. Bosch, Mirjam Langeveld, Vincent van der Wel, Saco de Visser, Sibren van den Berg   +14 more
wiley   +1 more source

A PHARMACEUTICAL GUIDE TO ADALIMUMAB BIOSIMILARS

FARMACIA, 2022
openaire   +1 more source

India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal, Vijay Kumar Chattu, Prakash Narayanan, Rahul Clare, Cherian Varghese   +4 more
wiley   +1 more source

Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches

Developing World Bioethics, Volume 26, Issue 1, Page 66-78, March 2026.
ABSTRACT This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching ...
Ubaka Ogbogu, Lauren Albrecht
wiley   +1 more source

Impact of biosimilar medicinal products in the EU pharmaceutical market [PDF]

Clinical Therapeutics, 2015
A. Grozdanova, K. Ancevska Netkovska, Z. Sterjev, Z. Naumovska, A. Kapedanovska Nestorovska, L.j Suturkova   +5 more
openaire   +1 more source

Biosimilar drugs - reimbursement regulations. Polish ISPOR chapter’s Therapeutic Programs and Pharmaceutical Care (TPPC) task force report

Journal of Health Policy & Outcomes Research, 2013
Objectives: Due to the increased number in biosimilar drugs getting marketing authorization, there is a question to be answered which reimbursement procedure should be followed. Methods: The TPPC task force has checked the approach to biosimilar drugs by WHO, at the EMA level and in a few countries worldwide.
openaire   +1 more source

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar to Eylea® (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases.
Neungseon Seo, Scott Kuhns, Dina A. Andrews, Alexander Colbert, Vincent Chow, Jennifer Liu   +5 more
doaj   +1 more source

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

AboutOpen
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been recently reimbursed by AIFA.
Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio   +2 more
openaire   +2 more sources